The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Iovance Biotherapeutics Inc shares valued at $42,250 were purchased by Vogt Frederick G on May 14 ’25. At $1.69 per share, Vogt Frederick G acquired 25,000 shares. The insider’s holdings grew to 374,646 shares worth approximately $0.66 million following the completion of this transaction.
Also, Maynard Ryan D sold 50,000 shares, netting a total of over 503,000 in proceeds. Following the sale of shares at $10.06 each, the insider now holds 7,500 shares.
Before that, Maynard Ryan D had added 50,000 shares to its account. In a trade valued at $503,104, the Director bought Iovance Biotherapeutics Inc shares for $10.06 each.
As published in a research note from UBS on May 16, 2025, Iovance Biotherapeutics Inc [IOVA] has been rated down from a Buy to a Neutral and the price target has been revised to $2. Analysts at Truist downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in mid May. As of May 09, 2025, Citizens JMP has decreased its “Mkt outperform” rating to a “Mkt perform” for IOVA. Earlier on October 24, 2024, UBS initiated its rating. Their recommendation was “a Buy” for IOVA stock.
Analyzing IOVA Stock Performance
During the last five days, there has been a surge of approximately 2.93%. Over the course of the year, Iovance Biotherapeutics Inc shares have dropped approximately -76.28%. Shares of the company reached a 52-week high of $8.1500 on 01/02/25 and a 52-week low of $1.6385 on 05/19/25.
Support And Resistance Levels for Iovance Biotherapeutics Inc (IOVA)
According to the 24-hour chart, there is a support level at 1.6700, which, if violated, would cause prices to drop to 1.5850. In the upper region, resistance lies at 1.8800. The next price resistance is at 2.0050. RSI (Relative Strength Index) is 31.42 on the 14-day chart, showing neutral technical sentiment.
